source
- Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drugThe second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts. Smaller biotechs are increasingly opting to launch their pr…
- BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…